Author name: Ananta Kar

Ananta is wrapping up her postgraduate studies in Comparative Literature whilst juggling a solid two-year writing career. She cut her teeth as a sports journalist before discovering her true passion: India's exploding gaming scene. These days, she's obsessed with how gaming culture is reshaping the country, and her academic research chops bring unexpected depth to every piece. Whether dissecting esports trends or exploring biologics in India, renewable energy, electric Vehicles & Smart Transportation topics, Ananta writes with the curiosity of a researcher and the energy of someone who genuinely loves what they do.

Avatar photo

From Passive Viewers to Active Participants: How Digital Platforms Transformed Entertainment

Remember when entertainment meant sitting quietly in front of a television, consuming whatever broadcasters decided to air? Those days are definitively over. Today’s audiences don’t just watch—they choose, create, interact, and shape the content they consume. The transformation from passive viewing to active participation represents perhaps the most significant shift in entertainment history, fundamentally changing […]

From Passive Viewers to Active Participants: How Digital Platforms Transformed Entertainment Read More »

India’s Indie Game Developers Are Building the Future in Bedrooms and Basements—Not Boardrooms

Whilst India’s major gaming studios chase mobile monetisation and licensed franchises, a quieter revolution unfolds in bedrooms, co-working spaces, and tiny studios across the country. Indie game developers—operating outside large corporate structures with minimal budgets and maximal passion—are building games the world hasn’t seen before. Titles like Raji: An Ancient Epic and Mumbai Gullies don’t

India’s Indie Game Developers Are Building the Future in Bedrooms and Basements—Not Boardrooms Read More »

Consumer Watchdog Crashes Supreme Court Gaming Battle: ABGP Says Ban Protects Lives, Not Just Business

The Supreme Court’s November 4th hearing on India’s gaming ban just got more complicated. The Akhil Bhartiya Grahak Panchayat (ABGP), a prominent consumer protection body, formally requested intervention in the case challenging the Promotion and Regulation of Online Gaming Act, 2025. While gaming companies argue that the blanket ban violates constitutional rights to conduct business,

Consumer Watchdog Crashes Supreme Court Gaming Battle: ABGP Says Ban Protects Lives, Not Just Business Read More »

GDAI Launches Policy Secretariat: India’s Gaming Industry Gets Its Voice

India’s gaming industry has exploded over the past five years, riding waves of affordable smartphones, faster internet, and millions of enthusiastic players. Yet despite this momentum, developers face persistent roadblocks—ambiguous regulations, unclear intellectual property protections, and a chronic shortage of skilled talent. The Gaming and Developers Association of India has decided it’s time to tackle

GDAI Launches Policy Secretariat: India’s Gaming Industry Gets Its Voice Read More »

India Unveils Formal Drug Approval Rules: A Regulatory Revolution Begins

India’s pharmaceutical industry has operated for decades under a cloud of regulatory uncertainty. Approval timelines were unpredictable, expert panel selections remained opaque, and companies often complained about inconsistent decisions that cost time and money. That era is ending. The Central Drugs Standard Control Organisation has unveiled India’s first comprehensive formal rules governing drug approval panels,

India Unveils Formal Drug Approval Rules: A Regulatory Revolution Begins Read More »

India Needs a Complete Drug Innovation Ecosystem—and the Clock Is Ticking

India’s pharmaceutical industry stands at a crossroads. For decades, the country has dominated global generic drug production, earning its reputation as the world’s pharmacy. Yet this comfortable position masks a critical vulnerability: the absence of a complete drug innovation ecosystem. While India supplies over 60% of global vaccines and churns out affordable medicines for millions,

India Needs a Complete Drug Innovation Ecosystem—and the Clock Is Ticking Read More »

Trump’s 100% Tariff on Branded Drugs: A Wake-Up Call for Indian Pharma

Former US President Donald Trump’s announcement of a 100% tariff on branded and patented pharmaceutical drugs has rattled India’s pharmaceutical sector. Effective 1st October 2025, this policy takes direct aim at biologics and complex generics—two of the fastest-growing segments for Indian manufacturers. India supplies nearly half the world’s generic medicines and leads global vaccine production,

Trump’s 100% Tariff on Branded Drugs: A Wake-Up Call for Indian Pharma Read More »

Can India Make VR Affordable for Everyone? The Race to Democratise Immersive Technology

Virtual Reality headsets remain luxury items in India, where a quality device costs more than three months’ salary for the average worker. Yet the same technology could revolutionise education in rural schools, train healthcare workers in remote villages, and provide entertainment experiences impossible through traditional screens. This contradiction defines India’s VR challenge: the technology offers

Can India Make VR Affordable for Everyone? The Race to Democratise Immersive Technology Read More »

AR and VR Gaming Explodes in India: Beyond Screens Into Immersive Virtual Worlds

Physical and digital worlds just collided in India’s gaming landscape, and the boundaries won’t return. Walk through any major Indian city today, and you’ll spot gamers chasing AR creatures overlaid on actual streets, whilst teenagers wearing VR headsets experience cricket matches from perspectives impossible in reality. This isn’t distant future speculation—Augmented Reality and Virtual Reality

AR and VR Gaming Explodes in India: Beyond Screens Into Immersive Virtual Worlds Read More »

India’s $60 Billion Biosimilar Bet: Why 2030 Could Make or Break Global Pharma Dominance

India conquered generic drugs and now stands at another pharmaceutical crossroads that could reshape global healthcare economics by decade’s end. Biosimilars—highly similar alternatives to expensive biologic drugs—represent India’s next frontier, with market projections exceeding $60 billion by 2030. These aren’t incremental improvements over existing generics—they’re affordable versions of cutting-edge cancer treatments, autoimmune therapies, and diabetes

India’s $60 Billion Biosimilar Bet: Why 2030 Could Make or Break Global Pharma Dominance Read More »

Scroll to Top